《欧洲肝脏研究学会临床实践指南：肝细胞癌的管理》勘误[《肝脏病学杂志》69(2018)182 - 236] - Suppr

Suppr

超能文献

Corrigendum to "EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma" [J Hepatol 69 (2018) 182-236].

出版信息

J Hepatol. 2019 Apr;70(4):817. doi: 10.1016/j.jhep.2019.01.020. Epub 2019 Feb 7.

DOI:10.1016/j.jhep.2019.01.020

PMID:30739718

Abstract

摘要

相似文献

Corrigendum to "EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma" [J Hepatol 69 (2018) 182-236].《欧洲肝脏研究学会临床实践指南：肝细胞癌的管理》勘误[《肝脏病学杂志》69(2018)182 - 236]

J Hepatol. 2019 Apr;70(4):817. doi: 10.1016/j.jhep.2019.01.020. Epub 2019 Feb 7.

Corrigendum to "EASL clinical practice guidelines on the management of hepatic encephalopathy" [J Hepatol 2022 (77) 807-824].《肝性脑病管理的EASL临床实践指南》勘误[《肝脏病学杂志》2022年（第77卷）807 - 824页]

J Hepatol. 2023 Nov;79(5):1340. doi: 10.1016/j.jhep.2023.09.004. Epub 2023 Sep 26.

Corrigendum to "EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis" [J Hepatol 69 (2018) 406-460].《失代偿期肝硬化患者管理的欧洲肝脏研究学会临床实践指南》勘误[《肝脏病学杂志》69 (2018) 406 - 460]

J Hepatol. 2018 Nov;69(5):1207. doi: 10.1016/j.jhep.2018.08.009. Epub 2018 Aug 29.

Corrigendum to "EASL clinical practice guidelines on the management of cystic liver diseases" [J Hepatol (77) 1083-1108].《欧洲肝脏研究学会关于囊性肝病管理的临床实践指南》[《肝脏病学杂志》(77) 1083 - 1108]勘误

J Hepatol. 2023 Nov;79(5):1338. doi: 10.1016/j.jhep.2023.09.003. Epub 2023 Sep 17.

Corrigendum to "EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma" [J Hepatol (79) (2023) 181-208].《欧洲肝脏研究学会-国际肝脏病协会肝内胆管癌管理临床实践指南》勘误 [《肝脏病学杂志》(79) (2023) 181 - 208]

J Hepatol. 2023 Nov;79(5):1342. doi: 10.1016/j.jhep.2023.09.006. Epub 2023 Sep 23.

Corrigendum to "EASL clinical practice guidelines on sclerosing cholangitis" [J Hepatol (77) 761-806].《硬化性胆管炎的欧洲肝脏研究学会临床实践指南》勘误 [《肝脏病学杂志》(77) 761 - 806]

J Hepatol. 2023 Nov;79(5):1339. doi: 10.1016/j.jhep.2023.09.005. Epub 2023 Sep 19.

Corrigendum to "EASL Clinical Practice Guidelines on haemochromatosis" [J Hepatol 2022 (77) 479-502].《血色病的欧洲肝脏研究学会临床实践指南》勘误 [《肝脏病学杂志》2022年（第77卷）第479 - 502页]

J Hepatol. 2023 Nov;79(5):1341. doi: 10.1016/j.jhep.2023.09.002. Epub 2023 Sep 26.

Corrigendum to 'EASL recommendations on treatment of hepatitis C: Final update of the series [J Hepatol 73 (2020) 1170-1218].《欧洲肝脏研究学会丙型肝炎治疗推荐：系列最终更新版》勘误 [《肝脏病学杂志》73卷（2020年）1170 - 1218页]

J Hepatol. 2023 Feb;78(2):452. doi: 10.1016/j.jhep.2022.10.006. Epub 2022 Dec 1.

Erratum to "EASL Clinical Practice Guidelines on acute-on-chronic liver failure" [J Hepatol 79 (2023) 461-491].《欧洲肝脏研究学会急性慢性肝衰竭临床实践指南》勘误 [《肝脏病学杂志》79 (2023) 461 - 491]

J Hepatol. 2024 Aug;81(2):370. doi: 10.1016/j.jhep.2024.03.012. Epub 2024 May 21.

Corrigendum to "Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis" [J Hepatol 71 (2019) 543-552].《纳武利尤单抗治疗晚期肝细胞癌：索拉非尼经治亚洲队列分析》的勘误[《肝脏病学杂志》71卷（2019年）543 - 552页]

J Hepatol. 2019 Dec;71(6):1278. doi: 10.1016/j.jhep.2019.09.013. Epub 2019 Oct 25.

引用本文的文献

Bicarbonate-integrated transarterial chemoembolization (TACE) in real-world hepatocellular carcinoma.现实世界中肝细胞癌的碳酸氢盐整合经动脉化疗栓塞术（TACE）

Signal Transduct Target Ther. 2025 Sep 1;10(1):281. doi: 10.1038/s41392-025-02400-x.

Prognostic predictive value of the preoperative systemic immunoinflammatory index combined with the neutrophil-to-lymphocyte ratio in patients with primary liver cancer undergoing transarterial chemoembolization.术前全身免疫炎症指数联合中性粒细胞与淋巴细胞比值对接受经动脉化疗栓塞的原发性肝癌患者的预后预测价值

Oncol Lett. 2025 Jun 27;30(3):414. doi: 10.3892/ol.2025.15160. eCollection 2025 Sep.

Navigating the complexities: challenges and opportunities in conversion therapy for advanced hepatocellular carcinoma.应对复杂性：晚期肝细胞癌转化治疗中的挑战与机遇

Clin Exp Med. 2025 May 18;25(1):169. doi: 10.1007/s10238-025-01698-9.

HES V2.0 surpasses GALAD for HCC detection: a review of multi-dimensional biomarker scores and studies.HES V2.0在肝癌检测方面超越GALAD：多维生物标志物评分及研究综述

Hepat Oncol. 2025 Dec;12(1):2494446. doi: 10.1080/20450923.2025.2494446. Epub 2025 Apr 30.

Identiﬁcation of a pyroptosis-related gene prognostic signature in patients with hepatocellular carcinoma.肝细胞癌患者中与细胞焦亡相关的基因预后特征的鉴定

J Gastrointest Oncol. 2025 Feb 28;16(1):128-145. doi: 10.21037/jgo-2024-954. Epub 2025 Feb 26.

The State of Systematic Therapies in Clinic for Hepatobiliary Cancers.肝胆癌临床系统治疗现状

J Hepatocell Carcinoma. 2024 Mar 27;11:629-649. doi: 10.2147/JHC.S454666. eCollection 2024.

The tumor burden score may be a discriminator in microwave ablation versus liver resection for hepatocellular carcinoma within the Milan criteria: a propensity score matching and inverse probability of treatment weighting study.对于米兰标准内的肝细胞癌，肿瘤负荷评分可能是微波消融与肝切除的一个鉴别因素：一项倾向评分匹配和治疗权重逆概率研究。

Front Oncol. 2024 Feb 16;14:1330851. doi: 10.3389/fonc.2024.1330851. eCollection 2024.

S100A family is a group of immune markers associated with poor prognosis and immune cell infiltration in hepatocellular carcinoma.S100A 家族是一组与肝癌预后不良和免疫细胞浸润相关的免疫标志物。

BMC Cancer. 2023 Jul 7;23(1):637. doi: 10.1186/s12885-023-11127-3.

A Novel Nomogram for Predicting the Overall Survival in Patients with Unresectable HCC after TACE plus Hepatic Arterial Infusion Chemotherapy.一种用于预测经动脉化疗栓塞术联合肝动脉灌注化疗后不可切除肝细胞癌患者总生存期的新型列线图。

Transl Oncol. 2023 Aug;34:101705. doi: 10.1016/j.tranon.2023.101705. Epub 2023 May 29.

Clinical Results, Risk Factors, and Future Directions of Ultrasound-Guided Percutaneous Microwave Ablation for Hepatocellular Carcinoma.超声引导下经皮微波消融治疗肝细胞癌的临床结果、危险因素及未来方向

J Hepatocell Carcinoma. 2023 May 15;10:733-743. doi: 10.2147/JHC.S409011. eCollection 2023.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验